"We see that the healthcare of tomorrow needs to encompass the overall patient journey, from diagnosis, through personalized treatment and monitoring in order to truly respond to patients’ overall needs."
JUPITER, Fla. (PRWEB) August 27, 2019
Advancements with Ted Danson will focus on recent developments in life science and drug development. This episode is scheduled to broadcast 4Q/2019. Check local listings for more information.
This segment of Advancements will explore Debiopharm, a biopharmaceutical research, development, investment and manufacturing company. The show will highlight how Debiopharm is working to champion the synergy between therapeutic and artificial intelligence (AI) innovation in the fight against cancer.
“Pharmaceutical companies can no longer afford to focus on drug development alone,” explained Mr. Thierry Mauvernay, President of Debiopharm. “We see that the healthcare of tomorrow needs to encompass the overall patient journey, from diagnosis, through personalized treatment and monitoring in order to truly respond to patients’ overall needs.”
Debiopharm’s pipeline includes a range of oncology therapies based on novel approaches to fight against disease including its chemo-radio-sensitizer treatment, which works by preventing cancer cells from evading the cell death process caused by chemo-radiotherapy and by improving anti-tumor immunity. Ongoing research also includes an FGFR Inhibitor, which targets cancers with specific genetic alterations of this cell receptor, regardless of the tumor type, currently in development along with a companion genetic diagnostic tool. Beyond therapeutics, the company has a strategic role in the development of smart healthcare technologies based on data and AI to improve treatment efficiency and ultimately patient quality of life.
“We’ve now arrived at a time in which smart digital companions to therapeutic approaches are actually making a real difference for the health of patients” stated Tanja Dowe, CEO Debiopharm Innovation Fund. “We believe that by remaining flexible, dynamic, and open to the emerging need for more ‘agile medicine,’ we will have a measurable impact on the future of patient healthcare.”
Debiopharm aims to develop innovative therapies that target high unmet medical needs in oncology and bacterial infections. Bridging-the-gap between disruptive discovery products and real-world patient reach, the company identifies high-potential compounds for in-licensing, clinically demonstrates their safety and efficacy, and then selects large pharmaceutical commercialization partners to maximize patient access globally.
For more information, visit http://www.debiopharm.com / or follow @DebiopharmNews at http://twitter.com/DebiopharmNews.
About Advancements and DMG Productions:
The Advancements series is an information-based educational show targeting recent advances across a number of industries and economies. Featuring state-of-the-art solutions and important issues facing today’s consumers and business professionals, Advancements focuses on cutting-edge developments, and brings this information to the public with the vision to enlighten about how technology and innovation continue to transform our world.
Backed by experts in various fields, DMG Productions is dedicated to education and advancement, and to consistently producing commercial-free, educational programming on which both viewers and networks depend.
For more information, please visit http://www.AdvancementsTV.com or call Richard Lubin at 866-496-4065.